Stockholm, 15 January 2010

XCounter notification of changes in significant shareholdings
XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from XR Invest AS that it has
purchased 11,818,181 XCounter shares representing 13.05 % of the issued share
capital of XCounter.


Stockholm, 03 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical
imaging, announces it has received notification from Whitehorse Investing Ltd
("Whitehorse") that it has purchased 4,100,000
XCounter shares representing
9.41 % of the issued share capital of XCounter, from HealthCap. The Company has
also received notification that funds managed by HealthCap RNS Number : 5924E
XCounter AB
22 December 2009

PRESS RELEASE




Stockholm, 22 December 2009



XCounter notification of changes in significant shareholdings


XCounter AB (AIM: XCT) ("XCounter"), a technology leader in the development of
photon counting X-ray detectors and tomosynthesis based 3D medical imaging,
announces today that it has received notification from Whitehorse Investing Ltd
("Whitehorse") that on the 21st December 2009 it purchased 734,786 XCounter
shares taking its total shareholding to 4,834,786 shares which represents 11.1 %
of XCounter.

XCOUNTER AB/XCT anytime soon wait for the A.A BUY.Co-development of the breast CT scanner provides a cost effective way for XCounter to progress the
development of the detector technology as, under the current proposals, Artemis intends to provide 1.75m
over a period of two years during the R&D phase of the project. Artemis would fund XCounter's detector
development in return for exclusivity for the PCT technology in the Mammo CT application.
Artemis has applied for a 2.8m grant from the German government (Bundesministerium f Bildung und
Forschung) to fund half of the project. It is currently anticipated that the German government will announce
the results of the grant application on or around 26 January 2010.
If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-
development agreement with Artemis in the first quarter of 2010 which will include provisions granting
Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental
phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that
time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector
components to be integrated into the completed Mammo CT device.
The Directors believe that the total initial market for the complete Mammo
CT systems to be 150m per annum